Hanmi will retain options for the drug, efinopegdutide, in Korea under the deal, in which Merck is paying the Seoul-based company $10 million upfront and up to $860 for development, regulatory and commercialization milestones.
Korea's news agency Yonhap reported that the executive, surnamed Lee, allegedly decided to tamper with evidence of a plot to inflate the value of Samsung's stake in a joint venture with a U.S. company.
The agency approved Truxima for three lymphoma indications, whereas European regulators approved it last year for all the same indications as the reference product, Roche's Rituxan.
Nature Medicine mouse study shows once-weekly GLP-1 receptor agonist slowed Parkinson's disease progression.
The number of cancer diagnostics companies these days seems innumerable, each hawking a new way to screen some subset of the populace for a grave disease. Their argument? Early diagnosis = early intervention = avoiding early death. But a great piece from FiveThirtyEight counters the idea of broad-scale cancer screening. It cites South Korea as a […]
Samsung Biologics, the drug manufacturing business that a South Korean conglomerate formed earlier this year with the help of pharmaceutical services firm Quintiles, is partnering on a $300 million initiative with Biogen Idec (NASDAQ:BIIB). The joint venture, which will be based in South Korea, will develop, manufacture and market biosimilars, biological products that are similar […]
By reducing administrative burden and redesigning workflows around human needs, it creates space for what matters most: connection between clinicians and patients.